 The stock price of Penumbra, a medical devices company focused on interventional therapies, has seen a 16 fall in a month, while it was down 10 last week. The company reported mixed Q4 results last month, with revenue of 204 million and adjusted EPS of 0.10 per share, compared to the consensus. 